Sign in
4

Changes in Ownership

Avalo Therapeutics, Inc. Filed Acc 0001578563-25-000198

Chief Financial Officer gave up 7,285 shares (to pay taxes)

  • Chief Financial Officer acquired 24,200 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Sullivan Christopher Ryan · Chief Financial Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2025-03-28 Exercise or conversion : show line 1 in the form +24,200 24,206 D
2025-03-28 Shares withheld for taxes : show line 2 in the form −7,285 $8.46 $61,631 16,921 D

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2025-03-28 Exercise or conversion : show line 3 in the form Restricted Stock Units −24,200 48,400 D
Loading xslF345X05/primary_doc.xml…